Charles Schwab Investment Management Inc Ventyx Biosciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 448,345 shares of VTYX stock, worth $914,623. This represents 0.0% of its overall portfolio holdings.
Number of Shares
448,345
Previous 488,717
8.26%
Holding current value
$914,623
Previous $1.07 Million
51.87%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding VTYX
# of Institutions
126Shares Held
45.4MCall Options Held
35.2KPut Options Held
40.6K-
Black Rock Inc. New York, NY4.77MShares$9.73 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.23MShares$8.64 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.51MShares$7.17 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$6.32 Million0.23% of portfolio
-
Sio Capital Management, LLC New York, NY2.58MShares$5.27 Million1.12% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $115M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...